id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
96,,,,,,,,,,,,,,,2024-05-11T15:52:27+06:00,BSH - H12211295852,,Trastuzumab,2023-03-07,,"Received NACT 4 cycles with AC on 04.10.2022> Started NACT C5 with Docetaxel +
Trastuzumab from 01.11.2022. C8 till 03.1.2023> Started Maintenace Trastuzumab from 07.03.2023, M12 is
due on 28.10.2023",2024-02-28,,2024-03-06,,2024-02-28,,,Breast,92,Upper middle class,BSBSC-240000092,MST. NAZMA KABIR,1730468540,1974-06-02,Female,,,,,Dr Ferdous Ara Begum,BSH,2.0,Switch Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.2- Upper-inner quadrant of breast,Breast,Right,,,Stable,Alive,CR,,,,,,,,,,,,,,,,,,,,,
